Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(170 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(86 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(78 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(27 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1375 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
LDN-214117
CAS:<p>LDN-214117 is a potent and selective ALK2 inhibitor.</p>Fórmula:C25H29N3O3Pureza:98% - 99.82%Cor e Forma:SolidPeso molecular:419.52RG14620
CAS:<p>RG14620 (Tyrphostin RG14620) is an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C14H8Cl2N2Pureza:99.82% - 99.87%Cor e Forma:SolidPeso molecular:275.13Dovitinib lactate
CAS:<p>Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM).</p>Fórmula:C24H27FN6O4Pureza:99.54% - 99.77%Cor e Forma:SolidPeso molecular:482.51LDN193189
CAS:<p>LDN193189 blocks BMP signaling by inhibiting ALK2/3; IC50: ALK1/2/3/6 = 0.8/0.8/5.3/16.7 nM.</p>Fórmula:C25H22N6Pureza:98% - 99.86%Cor e Forma:SolidPeso molecular:406.48AAL-993
CAS:<p>AAL-993: VEGFR inhibitor; IC50: 130 nM (1), 23 nM (2), 18 nM (3); weak on other tyrosine kinases; antiangiogenic & antitumor.</p>Fórmula:C20H16F3N3OPureza:99.65%Cor e Forma:SolidPeso molecular:371.36Protein kinase inhibitors 1
CAS:<p>Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.</p>Fórmula:C18H17N5O3SPureza:98%Cor e Forma:SolidPeso molecular:383.42(Rac)-IBT6A
CAS:<p>(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Fórmula:C22H22N6OPureza:99.24%Cor e Forma:SolidPeso molecular:386.45squarunkinA
CAS:<p>squarunkinA is a novel modulator of the UNC119-Cargo Interaction, potently and selectively inhibiting the binding of a myristoylated peptide representing the N-</p>Fórmula:C25H32F3N5O4Pureza:99.29%Cor e Forma:SolidPeso molecular:523.55Malantide acetate(86555-35-3 free base)
<p>Malantide acetate is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide</p>Fórmula:C74H128N22O23Pureza:>99.99%Cor e Forma:SolidPeso molecular:1693.97R-268712
CAS:<p>R-268712 is a potent ALK5 inhibitor with a 2.5 nM IC50, also targeting TGF-β type I receptor orally.</p>Fórmula:C20H18FN5OPureza:99.61%Cor e Forma:SolidPeso molecular:363.39MSDC 0160
CAS:<p>MSDC 0160 (CAY10415) is a prototype mTOT-modulating insulin sensitizer being used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.</p>Fórmula:C19H18N2O4SPureza:98.11% - 99.53%Cor e Forma:SolidPeso molecular:370.42UNC2541
CAS:<p>UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor.</p>Fórmula:C24H34FN7O2Pureza:98.33%Cor e Forma:SolidPeso molecular:471.57PKI 14-22 amide, myristoylated Acetate
<p>PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP. </p>Fórmula:C55H104N20O14Pureza:96.34%Cor e Forma:SolidPeso molecular:1269.54SU5205
CAS:<p>SU5205 is a VEGFR2 inhibitor.</p>Fórmula:C15H10FNOPureza:99.62% - 99.67%Cor e Forma:SolidPeso molecular:239.24Allitinib tosylate
CAS:<p>Allitinib tosylate (AST-1306) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, respectively.</p>Fórmula:C31H26ClFN4O5SPureza:98.46% - 98.68%Cor e Forma:SolidPeso molecular:621.08Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Cor e Forma:SolidPeso molecular:445.54PKG inhibitor peptide TFA (82801-73-8 free base)
<p>PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).</p>Fórmula:C40H75F3N18O12Pureza:100.00%Cor e Forma:SolidPeso molecular:1057.13Foretinib
CAS:<p>Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.</p>Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Cor e Forma:SolidPeso molecular:632.65Bemcentinib
CAS:<p>Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.</p>Fórmula:C30H34N8Pureza:97% - 99.8%Cor e Forma:SolidPeso molecular:506.64Vorolanib
CAS:<p>Vorolanib (X-82) is an orally active VEGFR/PDGFR dual inhibitor.</p>Fórmula:C23H26FN5O3Pureza:97.35%Cor e Forma:SolidPeso molecular:439.48Fruquintinib
CAS:<p>Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-</p>Fórmula:C21H19N3O5Pureza:98.84% - 99.89%Cor e Forma:SolidPeso molecular:393.39BIBF0775
CAS:<p>BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).</p>Fórmula:C31H34N4O2Pureza:99.45% - 99.79%Cor e Forma:SolidPeso molecular:494.63AG-13958
CAS:<p>AG-13958 (AG-013958) (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration.</p>Fórmula:C26H22FN7OPureza:99.4%Cor e Forma:SolidPeso molecular:467.5Motesanib
CAS:<p>Motesanib (AMG 706) orally blocks VEGFR, PDGFR, Kit, Ret; curbing angiogenesis and cancer cell growth.</p>Fórmula:C22H23N5OPureza:98% - 99.09%Cor e Forma:SolidPeso molecular:373.45zanubrutinib
CAS:<p>Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:98.42% - 99.76%Cor e Forma:SolidPeso molecular:471.55Belizatinib
CAS:<p>Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.</p>Fórmula:C33H44FN5O3Pureza:99.33% - 99.44%Cor e Forma:SolidPeso molecular:577.73Epidermal Growth Factor
CAS:<p>EGF binds EGFR, promotes cell growth & heals diabetic foot ulcers.</p>Fórmula:C270H401N73O83S7Pureza:97.17%Cor e Forma:SolidPeso molecular:6222Ibrutinib deacryloylpiperidine
CAS:<p>Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.</p>Fórmula:C17H13N5OPureza:99.47%Cor e Forma:SolidPeso molecular:303.32CP-380736
CAS:<p>CP-380736 (PF-00520893) inhibits EGFR, a kinase key in cancer-signaling pathways like MAPK, JNK, and Akt.</p>Fórmula:C14H18N2O5Pureza:99.68%Cor e Forma:White To Off-White SolidPeso molecular:294.3AZ191
CAS:<p>AZ191（IC50 of 17 nM） is an effective and specific DYRK1B inhibitor.</p>Fórmula:C24H27N7OPureza:98.04% - 99.65%Cor e Forma:SolidPeso molecular:429.52JI-101
CAS:<p>JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets VEGFR-2, PDGFR-β, and EphB4.</p>Fórmula:C22H20BrN5O2Pureza:99.41% - 99.97%Cor e Forma:SolidPeso molecular:466.33RU-301
CAS:<p>RU-301 is a novel pan-tam inhibitor</p>Fórmula:C21H19F3N4O4SPureza:98.87%Cor e Forma:SolidPeso molecular:480.46Ilorasertib
CAS:<p>Ilorasertib (ABT-348) inhibits Aurora kinases A/B/C & RET, PDGFRβ, Flt1 (IC50: 1-120 nM).</p>Fórmula:C25H21FN6O2SPureza:96.17% - 97.49%Cor e Forma:SolidPeso molecular:488.54AZ-5104
CAS:<p>AZ5104 is a potent EGFR inhibitor.</p>Fórmula:C27H31N7O2Pureza:98.40% - 99.59%Cor e Forma:Solid PowderPeso molecular:485.58SPP-86
CAS:<p>SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.</p>Fórmula:C16H15N5Pureza:99.53%Cor e Forma:SolidPeso molecular:277.32SB-505124
CAS:<p>SB505124 is a selective inhibitor of TGFβR for ALK4, ALK5.</p>Fórmula:C20H21N3O2Pureza:97.19% - 99.92%Cor e Forma:SolidPeso molecular:335.4eCF506
CAS:<p>eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)</p>Fórmula:C26H38N8O3Pureza:97.85% - 98.16%Cor e Forma:SolidPeso molecular:510.63EGFR-IN-12
CAS:<p>EGFR-IN-12 (EGFR Inhibitor) is a cell permeable and selective inhibitor of EGFR kinase (IC50: 21 nM) and blocks receptor autophosphorylation in cells.</p>Fórmula:C21H18F3N5OPureza:98.3% - 99.76%Cor e Forma:SolidPeso molecular:413.4VEGFR-2-IN-5
CAS:<p>VEGFR-2-IN-5 (UNC0064-12), multikinase inhibitor and has a -NH2 terminal linker for further synthesis.</p>Fórmula:C19H24N8Pureza:99.92%Cor e Forma:SolidPeso molecular:364.45Poziotinib hydrochloride
CAS:<p>Oral poziotinib HCl targets EGFR/HER mutants, inhibiting cancer cell growth.</p>Fórmula:C23H22Cl3FN4O3Pureza:99.69% - 99.81%Cor e Forma:SolidPeso molecular:527.8CNX-774
CAS:<p>CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).</p>Fórmula:C26H22FN7O3Pureza:97.35% - 99.11%Cor e Forma:SolidPeso molecular:499.5SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Cor e Forma:SolidPeso molecular:444.84cFMS Receptor Inhibitor II
CAS:<p>cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor</p>Fórmula:C23H20N4OPureza:99.8%Cor e Forma:SolidPeso molecular:368.43BLU9931
CAS:<p>BLU9931 is the first selective small molecule inhibitor of FGFR4.</p>Fórmula:C26H22Cl2N4O3Pureza:96.958% - 99.85%Cor e Forma:SolidPeso molecular:509.38Cediranib
CAS:<p>Cediranib (AZD2171) is a potent KDR tyrosine kinase inhibitor (IC50 < 1nM), also targets Flt1/4, PDGFRβ, c-Kit, and more selective for VEGFR.</p>Fórmula:C25H27FN4O3Pureza:97.21% - 99.94%Cor e Forma:SolidPeso molecular:450.51Rebastinib
CAS:<p>DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,</p>Fórmula:C30H28FN7O3Pureza:99.53% - 99.79%Cor e Forma:SolidPeso molecular:553.59Methyl 2,5-dihydroxycinnamate
CAS:<p>Methyl 2,5-dihydroxycinnamate is an EGF receptor-associated tyrosine kinases inhibitor.</p>Fórmula:C10H10O4Pureza:99.60%Cor e Forma:CrystallinePeso molecular:194.18HG-14-10-04
CAS:<p>HG-14-10-04 is a potent and specific ALK inhibitor.</p>Fórmula:C29H34ClN7OPureza:99.75% - >99.99%Cor e Forma:SolidPeso molecular:532.08PKG Substrate acetate(81187-14-6 free base)
<p>PKG Substrate acetate is a selective substrate for cGMP-dependent protein kinase (PKG).PKG Substrate is a selective substrate for protein kinase G (PKG) with a</p>Fórmula:C37H71N17O13Pureza:99.30%Cor e Forma:SolidPeso molecular:962.08UM-164
CAS:<p>UM-164 (DAS-DFGO-II), a highly potent c-Src inhibitor with a dissociation constant (Kd) of 2.7 nM, also effectively inhibits p38α and p38β.</p>Fórmula:C30H31F3N8O3SPureza:98.72% - 99.52%Cor e Forma:SolidPeso molecular:640.68KYL acetate(676657-00-4 free base)
<p>EphA4 inhibitor, Kd: 0.8 μM, IC50: 6.34 μM. Protects synapses and spines, maintains LTP. Long half-life: 8-12h. Neuroprotective.</p>Fórmula:C76H112N14O19Pureza:99.75%Cor e Forma:SolidPeso molecular:1525.78EOC317
CAS:<p>EOC317 (ACTB-1003) is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).</p>Fórmula:C27H26F5N7O3Pureza:98.00% - 99.26%Cor e Forma:SolidPeso molecular:591.53Saracatinib
CAS:<p>Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.</p>Fórmula:C27H32ClN5O5Pureza:98% - 99.63%Cor e Forma:SolidPeso molecular:542.03Tuxobertinib
CAS:<p>Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.</p>Fórmula:C29H29ClN6O4Pureza:99.22%Cor e Forma:SolidPeso molecular:561.03GW786034B
CAS:<p>Pazopanib HCl (Votrient) inhibits VEGFR1-3, PDGFR, FGFR, c-Kit, c-Fms with IC50 range 10-146 nM in cell-free assays.</p>Fórmula:C21H23N7O2S·HClPureza:99.87%Cor e Forma:SolidPeso molecular:473.98LOXO-195
CAS:<p>(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.</p>Fórmula:C20H21FN6OPureza:99.54%Cor e Forma:SolidPeso molecular:380.42Dovitinib lactate hydrate
CAS:<p>Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit).</p>Fórmula:C24H27FN6O4Pureza:99.82%Cor e Forma:SolidPeso molecular:482.51Olafertinib
CAS:<p>Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC.</p>Fórmula:C29H28F2N6O2Pureza:98.62% - 99.706%Cor e Forma:SolidPeso molecular:530.57ALK-IN-1
CAS:<p>ALK-IN-1 is a potent ALK inhibitor, demonstrating the ability to overcome Crizotinib resistance mediated by an L1196M mutation.</p>Fórmula:C26H34ClN6O2PPureza:99.74% - 99.80%Cor e Forma:SolidPeso molecular:529.01Zorifertinib
CAS:<p>Zorifertinib (AZD3759) is an orally active, effective and central nervous system-penetrant EGFR inhibitor.</p>Fórmula:C22H23ClFN5O3Pureza:98.20% - 99.36%Cor e Forma:White To Off-White SolidPeso molecular:459.9ML167
CAS:<p>ML167 (CID44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.</p>Fórmula:C19H17N3O3Pureza:99.82% - >99.99%Cor e Forma:SolidPeso molecular:335.36MTX-211
CAS:<p>MTX-211, an inhibitor of EGFR and PI3K, is used for the therapy of cancer and other diseases.</p>Fórmula:C20H14Cl2FN5O2SPureza:97.6% - >99.99%Cor e Forma:SolidPeso molecular:478.33TCS 359
CAS:<p>TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM.</p>Fórmula:C18H20N2O4SPureza:99.31%Cor e Forma:SolidPeso molecular:360.43GSK3179106
CAS:<p>GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM</p>Fórmula:C22H21F4N3O4Pureza:99.8% - 99.90%Cor e Forma:SolidPeso molecular:467.41Desmethyl Erlotinib hydrochloride
CAS:<p>Desmethyl Erlotinib hydrochloride (OSI 420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor.</p>Fórmula:C21H21N3O4·HClPureza:99.49%Cor e Forma:SolidPeso molecular:415.87Bafetinib
CAS:<p>Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.</p>Fórmula:C30H31F3N8OPureza:94.16% - 99.68%Cor e Forma:SolidPeso molecular:576.62XL 999
CAS:<p>Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor（KDR, Flt-1, FGFR1 and PDGFRα with IC50s of 4nM, 20nM, 4nM, 2 nM ,respectively）</p>Fórmula:C26H28FN5OPureza:98.24% - 99.55%Cor e Forma:SolidPeso molecular:445.53LDN-212854
CAS:<p>LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors.</p>Fórmula:C25H22N6Pureza:98% - 98.71%Cor e Forma:SolidPeso molecular:406.48SB 525334
CAS:<p>SB-525334 is a potent and selective inhibitor of the TGF-β1R and ALK5 (IC50: 14.3 nM).</p>Fórmula:C21H21N5Pureza:98.39% - ≥95%Cor e Forma:SolidPeso molecular:343.42ANA-12
CAS:<p>ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice.</p>Fórmula:C22H21N3O3SPureza:99.28% - 99.87%Cor e Forma:SolidPeso molecular:407.49Repotrectinib
CAS:<p>Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.</p>Fórmula:C18H18FN5O2Pureza:99.92% - >99.99%Cor e Forma:SolidPeso molecular:355.37XL228
CAS:<p>XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).</p>Fórmula:C22H31N9OPureza:99.07%Cor e Forma:SolidPeso molecular:437.54Tetramethylcurcumin
CAS:<p>Tetramethylcurcumin is a novel curcumin analog, is an effective inhibitors of STAT3 phosphorylation, DNA binding activity, and transactivation in vitro.it also</p>Fórmula:C25H28O6Pureza:97.69% - 99.94%Cor e Forma:SolidPeso molecular:424.49AG 555
CAS:<p>AG 555 (Tyrphostin B46) is an EGFR tyrosine kinase inhibitor.</p>Fórmula:C19H18N2O3Pureza:98.02% - 99.94%Cor e Forma:SolidPeso molecular:322.36PKA inhibitor fragment (6-22) amide Acetate
<p>PKA inhibitor fragment (6-22) amide Acetate is a synthetic peptide which selectively inhibits PKA activity by binding to its substrate site (IC50 < 2 nM).</p>Fórmula:C82H134N28O26Pureza:99.30%Cor e Forma:SolidPeso molecular:1928.11123C4
CAS:<p>123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 (Ki=0.65 μM)[1].</p>Fórmula:C43H47ClN8O6Pureza:98.94%Cor e Forma:SolidPeso molecular:807.34AMG 925
CAS:<p>AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.</p>Fórmula:C26H29N7O2Pureza:99.75%Cor e Forma:SolidPeso molecular:471.55ID-8
CAS:<p>ID-8, a DYRK inhibitor, sustains embryonic stem cell self-renewal in long-term culture.</p>Fórmula:C16H14N2O4Pureza:99.32%Cor e Forma:SolidPeso molecular:298.29UNC2025
CAS:<p>UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor.</p>Fórmula:C28H40N6OPureza:99.53% - 99.74%Cor e Forma:SolidPeso molecular:476.66AG-1478
CAS:<p>AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor.</p>Fórmula:C16H14ClN3O2Pureza:99.03% - 99.71%Cor e Forma:SolidPeso molecular:315.75AG 1406
CAS:<p>AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.</p>Fórmula:C16H18N2OPureza:98.12%Cor e Forma:SolidPeso molecular:254.33BFH772
CAS:<p>BFH772, a BAW2881 analogue, selectively inhibits VEGFR2 (IC50: 3 nM) and blocks RET, PDGFR, KIT phosphorylation (IC50: 30-160 nM).</p>Fórmula:C23H16F3N3O3Pureza:97.71% - 99.36%Cor e Forma:SolidPeso molecular:439.39Ceritinib dihydrochloride
CAS:<p>Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable, ATP-competitive inhibitor of ALK tyrosine kinase with antitumour effect.</p>Fórmula:C28H38Cl3N5O3SPureza:99.85% - 99.99%Cor e Forma:SolidPeso molecular:631.06ZAP-180013
CAS:<p>ZAP-180013 is an inhibitor of zeta-chain-associated protein kinase 70 (ZAP70,IC50 : 1.8 μM).</p>Fórmula:C19H17Cl2N3O4SPureza:98.89%Cor e Forma:SolidPeso molecular:454.33Su1498
CAS:<p>Su1498 (Tyrphostin SU 1498) is a selective inhibitor of the VEGF receptor 2, having negligible activity at several other serine/threonine and tyrosine kinases.</p>Fórmula:C25H30N2O2Pureza:99.54%Cor e Forma:SolidPeso molecular:390.52PD-166866
CAS:<p>PD-166866 is a selective FGFR tyrosine kinase inhibitor.</p>Fórmula:C20H24N6O3Pureza:98.29%Cor e Forma:SolidPeso molecular:396.44BIIB068
CAS:<p>BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.</p>Fórmula:C23H29N7O2Pureza:97.98%Cor e Forma:SolidPeso molecular:435.52Desmethyl Erlotinib
CAS:<p>Desmethyl Erlotinib (CP-473420) is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).</p>Fórmula:C21H21N3O4Pureza:97.92% - 98.62%Cor e Forma:SolidPeso molecular:379.417-Hydroxy-4H-chromen-4-one
CAS:<p>7-Hydroxy-4H-chromen-4-one (7-hydroxy-4-benzopyrone) is a Src kinase inhibitor (IC50 of <300 μM).</p>Fórmula:C9H6O3Pureza:97.65%Cor e Forma:SolidPeso molecular:162.14WHI-P258
CAS:<p>WHI-P258, a weak JAK3 inhibitor, is used as a negative control in drug development.</p>Fórmula:C16H15N3O2Pureza:99.66% - 99.92%Cor e Forma:SolidPeso molecular:281.31CHMFL-BMX-078
CAS:<p>CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.</p>Fórmula:C33H35N7O6Pureza:>99.99%Cor e Forma:SolidPeso molecular:625.67UNC2250
CAS:<p>UNC2250 is an effective and specific Mer inhibitor (IC50=1.7 nM).</p>Fórmula:C24H36N6O2Pureza:98.57% - 99.87%Cor e Forma:SolidPeso molecular:440.58BTK IN-1
CAS:<p>BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).</p>Fórmula:C19H21ClN6OPureza:97.38%Cor e Forma:SolidPeso molecular:384.86Tolebrutinib
CAS:<p>Tolebrutinib is an oral, selective BTK inhibitor, effective for MS research, with brain penetration and IC50s of 0.4/0.7 nM in cells.</p>Fórmula:C26H25N5O3Pureza:98.4% - 98.82%Cor e Forma:SolidPeso molecular:455.51Tesevatinib
CAS:<p>Tesevatinib (XL-647) is an oral, multi-targeted tyrosine kinase inhibitor.Cost-effective and quality-assured.</p>Fórmula:C24H25Cl2FN4O2Pureza:97.89% - 98.66%Cor e Forma:SolidPeso molecular:491.39PHA-680632
CAS:<p>PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively.</p>Fórmula:C28H35N7O2Pureza:98.2%Cor e Forma:SolidPeso molecular:501.62EBE-A22
CAS:<p>EBE-A22 (PD153035 Analog 63) is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.</p>Fórmula:C17H16BrN3O2Pureza:99.087% - 99.88%Cor e Forma:SolidPeso molecular:374.23CNX-2006
CAS:<p>CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.</p>Fórmula:C26H27F4N7O2Pureza:98.85% - 99.16%Cor e Forma:SolidPeso molecular:545.53Sapitinib
CAS:<p>Sapitinib (AZD-8931) , a reversible, ATP competitive inhibitor of EGFR(IC50=4 nM), ErbB2(IC50=3 nM) and ErbB3(IC50=4 nM), is more effective over Gefitinib or</p>Fórmula:C23H25ClFN5O3Pureza:98.89% - 99.83%Cor e Forma:SolidPeso molecular:473.93Alectinib
CAS:<p>Alectinib (RG-7853) is an ALK inhibitor that is selective, orally active, and ATP-competitive. Alectinib has antitumor activity. Cost-effective and quality-assured.</p>Fórmula:C30H34N4O2Pureza:98% - 99.38%Cor e Forma:SolidPeso molecular:482.62WZ-3146
CAS:<p>WZ3146: EGFR(L858R/E746_A750) inhibitor, IC50=2 nM, selective, doesn't block ERBB2(T798I).</p>Fórmula:C24H25ClN6O2Pureza:97.15%Cor e Forma:SolidPeso molecular:464.95CZC-8004
CAS:<p>CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.</p>Fórmula:C17H16FN5Pureza:99.29%Cor e Forma:SolidPeso molecular:309.34TPX-0046
CAS:<p>TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.</p>Fórmula:C21H21FN6O3Pureza:99.95%Cor e Forma:SolidPeso molecular:424.43BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Fórmula:C17H15N5Pureza:98.98%Cor e Forma:SolidPeso molecular:289.33Pelitinib
CAS:<p>Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).</p>Fórmula:C24H23ClFN5O2Pureza:98.37% - 99.84%Cor e Forma:Off-White SolidPeso molecular:467.92Selpercatinib
CAS:<p>"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."</p>Fórmula:C29H31N7O3Pureza:99.89% - >99.99%Cor e Forma:SolidPeso molecular:525.6GW2580
CAS:<p>GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.</p>Fórmula:C20H22N4O3Pureza:99.48% - >99.99%Cor e Forma:SolidPeso molecular:366.41NVP-ACC789
CAS:<p>ACC-789 (NVP-ACC789 (ZK202650); ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.</p>Fórmula:C21H17BrN4Pureza:99.44% - 99.63%Cor e Forma:SolidPeso molecular:405.29Olmutinib
CAS:<p>Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.</p>Fórmula:C26H26N6O2SPureza:99.63%Cor e Forma:SolidPeso molecular:486.59Almonertinib mesylate
CAS:<p>Almonertinib mesylate: EGFR tyrosine kinase inhibitor, targets EGFR-mutant non-small cell lung cancer.</p>Fórmula:C31H39N7O5SPureza:99.92%Cor e Forma:SolidPeso molecular:621.75LDN-193189 HCl
CAS:<p>LDN-193189 HCl (LDN193189 Hydrochloride) is a selective BMP type I receptor kinases inhibitor.</p>Fórmula:C25H22N6·HClPureza:99.49% - 99.53%Cor e Forma:SolidPeso molecular:442.94BMS-2
CAS:<p>BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.</p>Fórmula:C25H16F2N4O3Pureza:98.33%Cor e Forma:SolidPeso molecular:458.42(Rac)-JBJ-04-125-02
CAS:<p>(Rac)-JBJ-04-125-02 (JBJ-04-125-02) is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.</p>Fórmula:C29H26FN5O3SPureza:97.57%Cor e Forma:SolidPeso molecular:543.61Nintedanib
CAS:<p>Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/</p>Fórmula:C31H33N5O4Pureza:98% - 99.92%Cor e Forma:SolidPeso molecular:539.62Cyasterone
CAS:<p>Cyasterone (Cyasteron), a natural EGFR inhibitor, can inhibit the growth of A549 and MGC823 cells, via regulating EGFR signaling pathway, it may be a promising</p>Fórmula:C29H44O8Pureza:99.32% - 99.70%Cor e Forma:SolidPeso molecular:520.65Deucravacitinib
CAS:<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Fórmula:C20H19D3N8O3Pureza:98.52% - >99.99%Cor e Forma:SolidPeso molecular:425.46Leptomycin B
CAS:<p>Leptomycin B: potent CRM1 inhibitor, blocks protein nuclear export and cell cycle, antifungal, modifies cysteine.</p>Fórmula:C33H48O6Pureza:97.10% - 99.04%Cor e Forma:White Crystalline SolidPeso molecular:540.73Genistein
CAS:<p>Genistein (NPI 031L) is a natural soy isoflavone, a multi-targeted tyrosine kinase inhibitor. Genistein has antitumor effects. Cost effective and quality assured.</p>Fórmula:C15H10O5Pureza:98.22% - 99.64%Cor e Forma:Rectangular Or Six-Sided Rods From 60% Alcohol Dendritic Needles From Ether SolidPeso molecular:270.24Rostafuroxin
CAS:<p>Rostafuroxin (PST 2238) has been used in trials studying the treatment of Essential Hypertension.</p>Fórmula:C23H34O4Pureza:99.08% - >99.99%Cor e Forma:SolidPeso molecular:374.51Fenebrutinib
CAS:<p>Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).</p>Fórmula:C37H44N8O4Pureza:98.26% - 98.94%Cor e Forma:SolidPeso molecular:664.8CCT241736
CAS:<p>CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3</p>Fórmula:C22H23Cl2N7Pureza:96.2% - 99.81%Cor e Forma:SolidPeso molecular:456.37RET V804M-IN-1
CAS:<p>RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).</p>Fórmula:C19H16N6OPureza:97.94% - 99.62%Cor e Forma:SolidPeso molecular:344.37Mobocertinib
CAS:<p>Mobocertinib (tak788) is a potent inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent</p>Fórmula:C32H39N7O4Pureza:99.47% - 99.97%Cor e Forma:SolidPeso molecular:585.7Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Fórmula:C15H23N5O2S·C4H4O4Pureza:99.17%Cor e Forma:SolidPeso molecular:453.51CUDC-101
CAS:<p>CUDC-101 is a potent inhibitor of HDAC, EGFR and HER2 with IC50s of 4.4, 2.4 and 15.7 nM, respectively.</p>Fórmula:C24H26N4O4Pureza:95.76% - 99.17%Cor e Forma:SolidPeso molecular:434.49BBT594
CAS:<p>BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.</p>Fórmula:C28H30F3N7O3Pureza:99.57%Cor e Forma:SolidPeso molecular:569.58DDR1-IN-2
CAS:<p>DDR1-IN-2 (DDR1 inhibitor 7rh) (DDR1 inhibitor 7rh) is a potent, selective, ATP-competitive Discoidin domain receptor 1 (DDR1) inhibitor (IC50: 6.8 nM in cell-</p>Fórmula:C30H29F3N6OPureza:97.51%Cor e Forma:SolidPeso molecular:546.59Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Cor e Forma:Off-White SolidPeso molecular:485.94ODM-203
CAS:<p>ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity</p>Fórmula:C26H21F2N5O2SPureza:99.85%Cor e Forma:SolidPeso molecular:505.54Sitravatinib
CAS:<p>Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and</p>Fórmula:C33H29F2N5O4SPureza:98.9% - 99.85%Cor e Forma:SolidPeso molecular:629.68PD153035
CAS:<p>PD153035 (NSC-669364) hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR,</p>Fórmula:C16H14BrN3O2Pureza:98.47% - 99.29%Cor e Forma:SolidPeso molecular:360.21KHS101 hydrochloride
CAS:<p>KHS101 is a TACC3 inhibitor and can selectively induce a neuronal differentiation phenotype.</p>Fórmula:C18H22ClN5SPureza:99.6%Cor e Forma:SolidPeso molecular:375.92hVEGF-IN-1
CAS:<p>hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.</p>Fórmula:C34H43N7O2Pureza:99.76% - >99.99%Cor e Forma:SolidPeso molecular:581.75ENMD-2076
CAS:<p>ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.</p>Fórmula:C21H25N7Pureza:97.63% - ≥95%Cor e Forma:SolidPeso molecular:375.47Nazartinib
CAS:<p>Nazartinib (EGF816) (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (</p>Fórmula:C26H31ClN6O2Pureza:98.63% - ≥95%Cor e Forma:Solid PowderPeso molecular:495.02PD-089828
CAS:<p>PD 089828 inhibits FGFR1, PDGFRβ, EGFR (IC50s: 0.15-5.47 μM), and c-Src (IC50: 0.18 μM).</p>Fórmula:C18H18Cl2N6OPureza:97.39%Cor e Forma:SolidPeso molecular:405.28AST 487
CAS:<p>AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.</p>Fórmula:C26H30F3N7O2Pureza:98.17% - 99.56%Cor e Forma:SolidPeso molecular:529.56PD173955
CAS:<p>PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and</p>Fórmula:C21H16Cl2N4OSPureza:98.52% - 98.99%Cor e Forma:SolidPeso molecular:443.35FGFR2-IN-3
CAS:<p>FGFR2-IN-3 is an orally active selective FGFR2 inhibitor[1].</p>Fórmula:C28H24FN7O2Pureza:99.63%Cor e Forma:SoildPeso molecular:509.53PDGFR Tyrosine Kinase Inhibitor III
CAS:<p>PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III) (PDGF Receptor Tyrosine Kinase Inhibitor III) is a multikinase inhibitor that</p>Fórmula:C27H27N5O4Pureza:99.50%Cor e Forma:SoildPeso molecular:485.53Anumigilimab
CAS:<p>Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.</p>Pureza:95.75% (SEC-HPLC) - 98.43% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:143.86 kDaCavutilide
CAS:<p>Cavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.</p>Fórmula:C22H26FN3O3Pureza:99.82% - 99.85%Cor e Forma:SolidPeso molecular:399.458Indirubin Derivative E804
CAS:<p>Indirubin Derivative E804 is a potent insulin-like growth factor type 1 receptor (IGF1R) inhibitor with potential antitumor activity.</p>Fórmula:C20H19N3O4Pureza:98.54%Cor e Forma:SolidPeso molecular:365.38Gefitinib hydrochloride
CAS:<p>Obtustatin triacetate is an integrin derived from the venom of Vipera lebetina obtusa and is an α1β1 integrin and in vivo angiogenesis inhibitor.</p>Fórmula:C22H25Cl2FN4O3Pureza:99.8%Cor e Forma:SolidPeso molecular:483.36H-8 hydrochloride
CAS:<p>H-8 hydrochloride is a reversible and ATP-competitive PKA inhibitor. It can be used to study metabolic diseases.</p>Fórmula:C12H17Cl2N3O2SPureza:99.93%Cor e Forma:White To Off-White Crystalline SolidPeso molecular:338.25Tivozanib hydrochloride hydrate
CAS:<p>Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is a VEGFR tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, VEGFR-3 .</p>Fórmula:C22H22Cl2N4O6Pureza:98.66%Cor e Forma:SolidPeso molecular:509.34Toceranib
CAS:<p>Toceranib phosphate, orally active, inhibits RTK, PDGFR, VEGFR, Kit; Kis 5 nM PDGFRβ, 6 nM KDR; has antitumor effects.</p>Fórmula:C22H25FN4O2Pureza:97.14%Cor e Forma:SolidPeso molecular:396.46Canertinib dihydrochloride
CAS:<p>Canertinib dihydrochloride (PD-183805 dihydrochloride) is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and</p>Fórmula:C24H27Cl3FN5O3Pureza:99.13% - >99.99%Cor e Forma:SolidPeso molecular:558.86Brivanib (alaninate)
CAS:<p>Brivanib Alaninate (BMS-582664) is an alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic effect.</p>Fórmula:C22H24FN5O4Pureza:99.46% - 99.66%Cor e Forma:SolidPeso molecular:441.46NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Fórmula:C27H28F2N6OPureza:98%Cor e Forma:SolidPeso molecular:490.55BMS-690514
CAS:<p>BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.</p>Fórmula:C19H24N6O2Pureza:99.08%Cor e Forma:SolidPeso molecular:368.43Almonertinib hydrochloride
CAS:<p>Almonertinib hydrochloride (HS-10296 hydrochloride) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation.</p>Fórmula:C30H36ClN7O2Pureza:98.01% - 98.12%Cor e Forma:SolidPeso molecular:562.1(Rac)-SAR131675
CAS:<p>(Rac)-SAR131675 is an effective and specific VEGFR-3 inhibitor, which inhibited VEGFR-3 tyrosine kinase activity and VEGFR-3 autophosphorylation in HEK cells.</p>Fórmula:C18H22N4O4Pureza:98.34% - 99.1%Cor e Forma:SolidPeso molecular:358.39Naquotinib mesylate
CAS:<p>Naquotinib mesylate (ASP8273 (mesylate)) is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFR</p>Fórmula:C31H46N8O6SPureza:98%Cor e Forma:SolidPeso molecular:658.81Briquilimab
CAS:<p>Briquilimab is a humanized antibody that inhibits the SCF-KIT interaction, inducing mast cell apoptosis for research into inflammatory diseases.</p>Pureza:95% - 95%Cor e Forma:LiquidImgatuzumab
CAS:<p>Imgatuzumab (RG 7160) is a humanized anti-EGFR monoclonal antibody and immunomodulator for cancer research.</p>Cor e Forma:LiquidPeso molecular:145.0 (kDa)Anbenitamab
CAS:<p>Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.</p>Cor e Forma:LiquidAnti-Mouse GM-CSF Antibody (MP1-22E9)
<p>Anti-Mouse GM-CSF Antibody is a rat-derived IgG2a isotype inhibitor that targets mouse granulocyte-macrophage colony-stimulating factor (GM-CSF).</p>Pureza:98%Cor e Forma:Odour LiquidSerclutamab
CAS:<p>Serclutamab, a humanized chimeric monoclonal antibody of the IgG1-κ isotype, selectively targets the epidermal growth factor receptor (EGFR).</p>Pureza:98%Cor e Forma:LiquidZalutumumab
CAS:<p>Zalutumumab is a high-affinity fully human monoclonal antibody ,the extracellular domain of the EGFR squamous cell carcinoma of the head and neck (SCCHN).</p>Pureza:95%Cor e Forma:LiquidVeligrotug
CAS:<p>Veligrotug is an IV anti-IGF-1R antibody for thyroid eye disease, reducing diplopia and orbital inflammation, supporting autoimmune ophthalmopathy research.</p>Pureza:95% - 95%Cor e Forma:LiquidAnti-IGFBP2 Antibody (M14)
<p>Anti-IGFBP2 Antibody (M14) is a human monoclonal antibody inhibitor that binds with high affinity to IGFBP2 and prevents its interaction with IGF1. Additionally, Anti-IGFBP2 Antibody (M14) can inhibit the recruitment of human endothelial cells, thereby obstructing tumor progression in human metastatic cancers.</p>Cor e Forma:Odour Liquid6-Bn-cAMP
CAS:<p>6-Bn-cAMP is a selective activator of cAMP-dependent protein kinase (PKA) that does not activate Epac. Compared to cAMP, 6-Bn-cAMP enhances hydrolytic stability against PDE, esterases, and amidases, and significantly increases membrane permeability.</p>Fórmula:C17H18N5O6PCor e Forma:SolidPeso molecular:419.33Depatuxizumab
CAS:<p>Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, inhibit tumor growth,GBM,SCCHN.</p>Pureza:95%Cor e Forma:LiquidZanidatamab
CAS:<p>Zanidatamab (ZW25) is a bispecific, humanized monoclonal antibody that targets two distinct epitopes (ECD2 and ECD4) of the HER2 receptor, exhibiting anti-tumor</p>Cor e Forma:LiquidDusigitumab
CAS:<p>Dusigitumab (MEDI573) is a fully humanised monoclonal antibody targeting IGF1/IGF2, inhibiting IGF1/IGF2-induced IGF-1R phosphorylation.</p>Pureza:95% - 95%Cor e Forma:LiquidFigitumumab
CAS:<p>Figitumumab is a potent anti-IGF1R mAb (IC50=1.8 nM) showing promise in advanced lung squamous cell carcinoma.</p>Pureza:95%Cor e Forma:LiquidFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Pureza:95%Cor e Forma:LiquidFasinumab
CAS:<p>Fasinumab (anti-NGF mAb) is in Phase III trials for acute sciatica & knee OA. It significantly improves pain & function vs. placebo.</p>Pureza:95%Cor e Forma:LiquidBarzolvolimab
CAS:<p>Barzolvolimab (CDX 0159), a humanized IgG1 monoclonal antibody, blocks KIT activation and treats chronic urticaria.</p>Cor e Forma:LiquidPonezumab
CAS:<p>Ponezumab (PF-04360365), a humanized IgG2 antibody, lowers Aβ in the CNS & boosts mice memory. Used in Alzheimer's research.</p>Cor e Forma:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Pureza:98%Cor e Forma:LiquidFulranumab
CAS:<p>Fulranumab (AMG-403) is a humanised monoclonal antibody targeting NGF, analgesic effects, and can be used for the study of chronic pain.</p>Pureza:95%Cor e Forma:LiquidFrunevetmab
CAS:<p>Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. Feline osteoarthritis (OA).</p>Pureza:95% - 95%Cor e Forma:LiquidTanezumab
CAS:<p>Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF，pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.</p>Pureza:95%Cor e Forma:LiquidNamilumab
CAS:<p>Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF. rheumatoid arthritis and active axial spondyloarthritis.</p>Pureza:95%Cor e Forma:LiquidElgemtumab
CAS:<p>Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation antitumour.</p>Pureza:95%Cor e Forma:LiquidIzalontamab
CAS:<p>Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.</p>Pureza:95%+ - 95%+Cor e Forma:LiquidBecotatug
CAS:<p>Becotatug (JMT-101) is an IgG1 antibody that targets EGFR and can be conjugated to Afatinib and Osimertinib, functioning as a synthetic antibody-drug conjugate</p>Pureza:95% - 95%Cor e Forma:LiquidFutuximab
CAS:<p>Futuximab, a chimeric monoclonal antibody, targets distinct epitopes on the epidermal growth factor receptor (EGFR), exhibiting antineoplastic activity [1].</p>Pureza:95% - 95%Cor e Forma:LiquidCabiralizumab
CAS:<p>Cabiralizumab is an anti-CSF1R monoclonal antibody that enhances T cell infiltration, inhibits osteoclasts, and is used in RA and immune-oncology research.</p>Pureza:95% - 95%Cor e Forma:LiquidAnti-Mouse CD117 Antibody
<p>Anti-Mouse CD117 Antibody, a rat-derived IgG2b isotype, acts as an inhibitor specific to the mouse CD117 antigen.</p>Pureza:98%Cor e Forma:Odour Solidlavendustin A
CAS:<p>lavendustin A (RG-14355) is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.</p>Fórmula:C21H19NO6Pureza:98%Cor e Forma:Off-White SolidPeso molecular:381.38Dovitinib Dilactic Acid
CAS:<p>Dovitinib dilactic acid: multitarget RTK inhibitor for FLT3/c-Kit (IC50=1-2 nM), FGFR1/3, VEGFR1-4 (IC50=8-13 nM), less effective on InsR, EGFR. Phase 4.</p>Fórmula:C21H21FN6O·2C3H6O3Pureza:98%Cor e Forma:SolidPeso molecular:572.598-MA-cAMP
CAS:<p>8-MA-cAMP (8-Methylamino-cAMP) is a cyclic adenosine monophosphate analog that acts as a site-selective PKA agonist, exhibiting similar affinity for the B site of both Type I and Type II protein kinase A. When used in conjunction with analogs that preferentially target site A, such as 8-piperidinyl cAMP, 8-MA-cAMP facilitates selective stimulation of Type I enzymes.</p>Fórmula:C11H15N6O6PCor e Forma:SolidPeso molecular:358.25S961
CAS:<p>S961: High-affinity IR antagonist; IC50: HIR-A 0.048 nM, HIR-B 0.027 nM, HIGF-IR 630 nM.</p>Fórmula:C211H297N55O71S2Pureza:98%Cor e Forma:SolidPeso molecular:4804.13CSF1R-IN-19
CAS:<p>CSF1R-IN-19 is a robust inhibitor of CSF1R that influences the exchange of inflammatory factors between TAMs and glioma cells. It holds potential for cancer research [1].</p>Fórmula:C20H27N7OCor e Forma:SolidPeso molecular:381.47IGF-1R modulator 1
CAS:<p>IGF-1Rmodulator 1 (Example 5) is an IGF-1R modulator featuring an EC50 of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), and 0.39 μM (TrkB). This compound is useful in research on diseases characterized by impaired signaling of neurotrophic and/or other trophic factors, such as Alzheimer's disease.</p>Fórmula:C22H17N3O4Cor e Forma:SolidPeso molecular:387.39Icotinib
CAS:<p>Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.</p>Fórmula:C22H21N3O4Pureza:99.76% - 99.94%Cor e Forma:SolidPeso molecular:391.42ZM323881 hydrochloride
CAS:<p>ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.</p>Fórmula:C22H19ClFN3O2Pureza:99.43%Cor e Forma:SolidPeso molecular:411.868-Chloro-cAMP sodium
CAS:<p>8-Chloro-cAMP sodium is a cAMP analog that induces growth arrest and modulates cAMP-dependent PKA activity. This compound also exhibits anticancer activity.</p>Fórmula:C10H10ClN5NaO6PCor e Forma:SolidPeso molecular:385.63Icotinib Hydrochloride
CAS:<p>Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.</p>Fórmula:C22H22ClN3O4Pureza:99.89%Cor e Forma:SolidPeso molecular:427.88GW843682X
CAS:<p>GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).</p>Fórmula:C22H18F3N3O4SPureza:99.92%Cor e Forma:SolidPeso molecular:477.46TAK-285
CAS:<p>TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.</p>Fórmula:C26H25ClF3N5O3Pureza:99.73%Cor e Forma:SolidPeso molecular:547.96CP-547632
CAS:<p>CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.</p>Fórmula:C20H24BrF2N5O3SPureza:99.39%Cor e Forma:SolidPeso molecular:532.4BMS-754807
CAS:<p>BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.</p>Fórmula:C23H24FN9OPureza:99.69% - 99.94%Cor e Forma:SolidPeso molecular:461.49AMG-458
CAS:<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Cor e Forma:SolidPeso molecular:539.58CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Cor e Forma:SolidPeso molecular:562.54DDR-TRK-1
CAS:<p>DDR-TRK-1 is a selective discoid domain receptor 1 (DDR1) inhibitor with IC50 value of 9.4 nM. DDR-TRK-1 also inhibits the TRK family.</p>Fórmula:C26H23F3N6OPureza:99.63%Cor e Forma:SolidPeso molecular:492.5EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Cor e Forma:SolidPeso molecular:571.69
